Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...
Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.
Diabeloop announced today that its DBLG2 algorithm for automated insulin delivery has received FDA 510(k) clearance.
DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to ...
The model, 34, and the comedian, 37, who are parents to daughter Elsie, two, became engaged when he popped the question in ...
Senseonics earns a buy with Eversense 365 driving growth, Q3 revenue up 90% YoY, gross margin expansion, and Ascensia ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose ...
Discover why DexCom (DXCM) could rebound in 2025. Explore buyback plans, growth potential, and investment insights in the ...
Dexcom’s G6 (left) and G7 (right) side-by-side. [Image from Dexcom] A Dexcom (NSDQ:DXCM) communication on its website states that it will soon cease manufacturing for its G6 continuous glucose monitor ...
IEEE Spectrum on MSN
Why the most accurate glucose monitors are failing some users
In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings. The recall affects approximately 3 million sensors and was caused by an ...
All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Gizmodo may earn an affiliate commission. Reading time 7 minutes There ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback